Perkin-Elmer
This article was originally published in The Gray Sheet
Executive Summary
Perkin-Elmer: PerSeptive Biosystems subsidiary plans to redeem all of its 8-1/4% convertible subordinated notes due 2001 on March 23. The redemption price will be paid in cash and equal $1,055.81 per $1,000 principal amount of the notes, "which represents the redemption premium and aggregate principal plus accrued and unpaid interest to the redemption date," the firm states. The notes, for which the aggregate outstanding principal amount is $27.2 mil., are joint obligations of Perkin-Elmer and PerSeptive Biosystems, which was acquired by Perkin-Elmer on Jan. 22 ("The Gray Sheet" Jan. 26, In Brief)...
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.